Developmental Outcomes
Clinical Utility of Serum Biomarkers for the Management of Neonatal Hypoxic Ischemic Encephalopathy (HIE).
Sponsor: American Heart Association
This observational or N/A phase trial investigates Hypoxic-Ischemic Encephalopathy and is currently completed. American Heart Association leads this study, which shows 14 recorded versions since 2014 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
14 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Dec 2021 — Jul 2024 [monthly]
Completed
-
Jan 2021 — Dec 2021 [monthly]
Completed
-
Nov 2020 — Jan 2021 [monthly]
Completed
▶ Show 9 earlier versions
-
Feb 2020 — Nov 2020 [monthly]
Completed
-
Jan 2019 — Feb 2020 [monthly]
Completed
Status: Enrolling By Invitation → Completed
-
Jun 2018 — Jan 2019 [monthly]
Enrolling By Invitation
-
May 2018 — Jun 2018 [monthly]
Enrolling By Invitation
-
Apr 2018 — May 2018 [monthly]
Enrolling By Invitation
Phase: NA → None
-
Dec 2017 — Apr 2018 [monthly]
Enrolling By Invitation NA
-
Aug 2017 — Dec 2017 [monthly]
Enrolling By Invitation NA
-
Mar 2017 — Aug 2017 [monthly]
Enrolling By Invitation NA
-
Jan 2017 — Mar 2017 [monthly]
Enrolling By Invitation NA
First recorded
Nov 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- American Heart Association
- University of Florida
For direct contact, visit the study record on ClinicalTrials.gov .